Converging evidence points to adaptive changes in neuroplasticity and gene expression as mediators of therapeutic action of antidepressants. Activation of cAMP response-element binding protein (CREB) and CREB-regulating signalling are considered main effectors in these mechanisms. We analysed the temporal profile of intracellular changes induced by antidepressants, by measuring activation of major CREBregulating signalling cascades and activation (Ser 133 phosphorylation) of CREB. The main aims of the study were to investigate how these different variables are modulated with time, whether stronger activation of signalling cascades corresponds to stronger activation of CREB, and whether these changes are different in distinct brain areas. Rat groups were treated for 1, 2 or 3 wk with the antidepressants fluoxetine or reboxetine ; in additional groups drug treatment was followed by a washout week (3+1). Activation of CREB and major effectors in signalling cascades were analysed by Western blot analysis with phospho-antibodies, in nuclear and cytosolic fractions from hippocampus and prefrontal/frontal cortex (P/FC). Surprisingly, CREB activation was already maximal after 1-wk treatment. In hippocampus early and stronger CREB activation was consistent with early and stronger activation of signalling. For both drugs, the profile of activation in P/FC was different from that observed in hippocampus. The results also showed that, contrary to the activatory role of MAP-ERKs and CaM kinase IV, nuclear aCaM kinase II was inactivated in parallel with activation of CREB.
Introduction
Although antidepressants represent the mainstay in the treatment of depression and mood disorders, a unified theoretical framework explaining their mechanism is still lacking, in parallel with the lack of knowledge of biological underpinnings of psychiatric pathology (Agid et al. 2007 ; Mathew et al. 2008 ; McClung & Nestler, 2008 ; Pittenger & Duman, 2008 ; Racagni & Popoli, 2008) . Converging lines of evidence point to adaptive changes in post-receptor signalling and gene expression, induced by acute increase of monoamine availability, as mediators of the delayed therapeutic action of antidepressants. The transcription factor cAMP response element-binding protein (CREB) is the most thoroughly studied regulator of gene expression. CREB is involved in a large variety of processes, including outgrowth of neuronal processes, learning and memory, induction of neurotrophic cellular programmes, regulation of circadian rhythms, neurogenesis, pathophysiology of neuropsychiatric and neurodegenerative disorders, mechanisms of psychotropic drugs (Carlezon et al. 2005 ; De Cesare et al. 1999 ; Lonze & Ginty, 2002 ; Mayr & Montminy, 2001 ; McClung & Nestler, 2008 ; Pittenger & Duman, 2008 ; West et al. 2002) . CREB transcriptional activity is induced by multiple signalling cascades, in turn activated by different stimuli that phosphorylate its Ser 133 residue. Additional residues can be phosphorylated and regulate CREB activation, but these additional events have been less characterized (Gau et al. 2002 ; Johannessen et al. 2004 ; McClung & Nestler, 2008 ; Parker et al. 1998 ; Tardito et al. 2006 ; Wu & McMurray, 2001) . There is general agreement that chronic antidepressants stimulate CREB function, although conflicting results have been reported, and this protein has become a type of readout system in the study of antidepressant mechanisms (Carlezon et al. 2005 ; Duman & Monteggia, 2006 ; Malberg & Blendy, 2005 ; Pittenger & Duman, 2008 ; Tardito et al. 2006) . It is generally assumed that the timing of activation of CREB during antidepressant treatment is somewhat consistent with the delayed action of these drugs (e.g. 2-3 wk or longer), although it was reported that increased CREB phosphorylation may also be detected after acute treatment with fluoxetine (Flx), reboxetine (Rbx) or citalopram (Rantamaki et al. 2007 ). Indeed, a thorough analysis of the timing of CREB activation during antidepressant treatment has not been performed so far, as was done for brain-derived neurotrophic factor (BDNF) expression (Coppell et al. 2003 ; De Foubert et al. 2004 ; Donnici et al. 2008 ; Larsen et al. 2008 ; Russo-Neustadt et al. 2005) . Moreover, previous evidence suggests that activation of multiple signalling cascades impinging on CREB is required for induction of persistent changes in gene expression (Deisseroth & Tsien, 2002 ; Johannessen et al. 2004 ; McClung & Nestler, 2008) . Activation of multiple cascades could be a way of signalling stimuli of greater significance, which deserve to leave a deeper and more persistent trace in gene expression and cellular function. It is not known whether this may apply to the action of antidepressants.
Therefore, in this work we investigated the timing of induction of CREB Ser 133 phosphorylation and analysed whether the activation of signalling cascades promoting phosphorylation (activation) of CREB is consistent with this timing. We treated rats with two different antidepressants endowed with complementary mechanisms : Flx, a selective serotonin reuptake inhibitor (SSRI), and Rbx, a selective norepinephrine reuptake inhibitor (NRI). The drug treatments were carried out for 1, 2 and 3 wk.
Previous compelling evidence has shown that in neurons activity-dependent phosphorylation of CREB at Ser 133 is mainly induced by activation of the Rasmitogen activated protein (MAP) kinase and the calcium/calmodulin (CaM)-dependent kinase cascades (Bito et al. 1996 ; Ghosh et al. 1994 ; Kasahara et al. 2001 ; Lee et al. 2005 ; for a discussion see Tardito et al. 2006) . Components of the extracellular signal-regulated kinases (ERK)-MAP kinase cascade have been implicated in behavioural as well as molecular/cellular effects of antidepressants (Duman et al. 2007 ; Saarelainen et al. 2003) . Moreover, we have recently shown that chronic antidepressant treatments significantly activate ERK-MAPK and CaM kinase IV cascades, while chronic lithium down-regulates CaM kinase IV expression and activation (Tardito et al. 2007 ; Tiraboschi et al. 2004b) . Therefore, in the present study the time-course of activation of major components of these cascades during antidepressant treatment was assessed.
Another relevant question that has seldom been asked is what happens to these intracellular mechanisms when antidepressant treatments are discontinued. For this reason we added here a further week of washout (3+1 wk) to the 3-wk drug treatment.
In summary, regarding the action of antidepressants, in this study we asked the following questions :
(1) What is the time-course of CREB activation and CREB-regulating signalling during antidepressant treatment? Is activation of CREB linked to activation of multiple cascades? (2) What is left of these intracellular changes after a further 1-wk washout? (3) Is the recruiting of CREB-regulating signalling different in distinct brain areas?
We believe that attempting to answer these questions may contribute to further explaining the mechanism of antidepressants, as well as finding new targets for pharmacological treatments.
Methods

Drug treatment and preparation of total extract and nuclear fraction
Experiments complied with guidelines for use of experimental animals of European Community Council Directive 86/609/EEC. Groups of 12 male SpragueDawley rats (aged 6 wk at start of treatment) (Charles River Calco, Italy) were treated with vehicle (water), Flx or Rbx at 10 mg/kg rat weight/d, delivered in drinking water. These doses of Flx and Rbx were chosen because similar doses have been found to be efficacious on cellular, molecular or functional readouts of antidepressants in previous studies (Barbiero et al. 2007 ; Barbon et al. 2006 ; Bonanno et al. 2005 ; Coppell et al. 2003 ; Parini et al. 2005) . The average water intake per day for each cage (two rats) was recorded for 4 d before starting and throughout the treatment, and the drug solutions were changed every 2 d according to the animals' weight, as reported in previous studies (Dow et al. 2005) . Rats were divided in nine experimental groups : control (water), 1-wk treatment (Flx or Rbx), 2-wk treatment (Flx or Rbx), 3-wk treatment (Flx or Rbx) and 3-wk treatment (Flx or Rbx) plus 1-wk drug washout (Fig. 1 ). All the animals were sacrificed at the same age. Hippocampus (HPC) and the whole frontal lobe, referred to as prefrontal/ frontal cortex (P/FC), were quickly excised on ice as previously described (Barbon et al. 2006 ; Glowinski & Iversen, 1966) . The tissue was homogenized 1 : 10 (w/v) in homogenization buffer (HB) [0.28 M sucrose, 10 mM Hepes (pH 7.4), 0.1 mM EGTA, 20 mM NaF, 5 mM Na 2 PO 4 , 1 mM Na 2 VO 4 , 2 ml/ml protease inhibitor cocktail (Sigma-Aldrich, USA)]. Total extracts were centrifuged for 5 min at 1000 g and the resulting pellets, enriched in nuclei (P1), were resuspended in lysis buffer [120 mM NaCl, 20 mM Hepes (pH 7.4), 0.1 mM EGTA, 0.1 mM DTT, protease and phosphatase inhibitors as in HB]. Nuclear fraction was previously characterized as to protein markers (Barbiero et al. 2007) .
Western blot analysis
Western blot analysis was performed as described previously (Tiraboschi et al. 2004b) , by incubating PVDF membranes, containing electrophoresed proteins from either total homogenates or P1 nuclear fractions (n=3-5 in triplicate), with monoclonal antibodies for phospho-Ser 133 CREB 1 : 1000, p44/42 and phospho-p44/42 MAPK (Thr 202 /Tyr 204 ) 1 : 1000 (Cell Signaling, USA), aCaM kinase IV 1 : 1000 (Transduction Laboratories, USA), aCaM kinase II 1 : 1000 (Chemicon International, USA), phospho-Thr 286 aCaM kinase II 1 : 1000, (Affinity Bioreagents, USA), b-actin 1 : 5000 (Sigma-Aldrich) and polyclonal antibodies for CREB 1 : 1000 (Cell Signaling), phospho-Thr 196 aCaM kinase IV 1 : 500 (Santa Cruz Biotechnologies, USA). Following incubation with peroxidase-coupled secondary antibodies, protein bands were detected by using ECL (GE Healthcare, Sweden). Standard curves were obtained by loading increasing amounts of samples on gels as described previously (Tiraboschi et al. 2004b) . All protein bands used were within the linear range of standard curves and normalized for b-actin level in the same membrane. Standardization and quantitation was as reported previously, except that Quantity One software (Bio-Rad Laboratories, USA) was used.
Statistical analysis
All data were analysed by using two-way analysis of variance (ANOVA) for the variable treatment (Flx/ Rbx) and the variable time (control, 1 wk, 2 wk, 3 wk, 3+1 washout wk). If the ANOVA revealed significant group differences, post-hoc Bonferroni tests were performed to elucidate the pattern of group differences. Significance was assumed at p<0.05. Statistical analysis of the data was carried out using GraphPad Prism 4 (GraphPad Software Inc., USA).
Results
Early activation of nuclear CREB by Flx and Rbx
In order to assess the effect of the two different antidepressant drugs on nuclear CREB during the treatment, we measured the protein expression level, and phosphorylation state of Ser 133 in HPC and P/FC of rats treated with Flx and Rbx. Regarding the protein expression level in HPC, two-way ANOVA (2WA) showed a significant effect of time (F 4,66 =10.43, p< 0.0001), but not of drug, and a significant timerdrug interaction (F 4,66 =3.41, p<0.05). In P/FC there was a significant effect of time (F 4,101 =2.58, p<0.05) and a significant effect of drug (F 1,101 =4.48, p<0.05). According to Bonferroni post-hoc tests, Flx did not have major effects on CREB expression in the first 2 wk (Fig. 2 a, b) ; however, Flx reduced CREB expression in HPC and up-regulated in P/FC at week 3. Rbx induced a transient increase at week 1 in HPC and then down-regulated CREB (significant only at week 4) ; CREB down-regulation by Rbx at week 3+1 was also observed in P/FC.
The two drugs up-regulated Ser 133 CREB phosphorylation in both areas ( Fig. 2 c, d ). In HPC 2WA showed an effect of time (F 4,36 =24, 37, p<0.0001), drug (F 1,36 =21.80 ; p<0.0001) and timerdrug interaction (F 4,36 =17, 63, p<0.0001) . Surprisingly, a marked and significant increase of phospho-CREB (pCREB) in HPC was induced at week 1 with both Flx and Rbx ; pCREB was still elevated in the following weeks : at week 2, only Flx showed a significant effect, at week 3 the increase was significant for both drugs. After the washout week (3+1) pCREB levelled off for Rbx but was still maximal for Flx. A similar effect was found in P/FC, where 2WA showed a significant timerdrug interaction (F 4,36 =3.92, p<0.01) and a significant effect of time (F 4,36 =7, 90, p<0.0001), although the extent of increase in CREB phosphorylation was smaller compared with HPC. pCREB was significantly increased at all time-points for Flx. The increase induced by Rbx was significant starting at week 2 and remained significant at week 3, but not after washout.
Early activation of Erk1/2 MAP kinases by Flx and Rbx in HPC
The MAPK cascades are important components in the regulation of neuroplasticity and gene expression, including CREB activation (Sweatt, 2004 ; Thomas & Huganir, 2004 ; West et al. 2002) , and have recently been implicated in behavioural and molecular effects of antidepressants (Duman et al. 2007 ; Saarelainen et al. 2003 ; Tiraboschi et al. 2004b ). Here we measured the expression and phosphorylation of the two kinases ERK1/2, in order to elucidate the timing of their (Arthur & Cohen, 2000 ; De Cesare et al. 1998 ; Deak et al. 1998) , we analysed ERKs in both total extract and nuclear fraction.
HPC total extract
As shown in Fig. 3(a, b) , the two drug treatments did not induce changes in ERK1 protein levels throughout the treatment. For ERK2, 2WA showed a significant effect of time (F 4,100 =3, 25, p<0.05), drug (F 1,100 =54, 14, p<0.0001) and timerdrug interaction (F 4,100 =11.08, p<0.0001), with reduction of ERK2 by Flx and increase by Rbx, the latter only at weeks 2-3. After drug washout ERK2 returned to basal level in the Rbx group, but remained significantly lower in the Flx group. Phosphorylation was differently affected by the two drugs in HPC total extract, where both drugs had already activated ERK1/2 at week 1 ; this activation was sustained for Flx throughout treatment but only transient for Rbx (Fig. 3c, d ). Rbx induced a significant increase at week 1 and after washout. For pERK2, 2WA showed a significant effect of drug (F 1,115 =8.49, p<0.005) and time (F 4,115 =10.05, p<0.0001), with a significant activation of the kinase at week 1 by both Flx and Rbx, that was sustained only with Flx in the following weeks.
HPC nuclear fraction
Flx down-regulated ERK1/2 starting at week 2 (Fig. 4a, b) . For ERK1 2WA showed a significant effect of drug (F 1,80 =14.49, p<0.001) and post-hoc comparisons showed significant reduction at weeks 2-3. Regarding ERK2, there was a significant effect of time (F 4,77 =3.06, p<0.05), drug (F 1,77 =50.14, p<0.0001) and timerdrug interaction (F 4,77 =9.76, p<0.0001). Rbx reduced ERK2 levels at week 1 and increased it at week 3+1, whereas Flx reduced ERK2 expression starting with week 2. Regarding ERK1/2 phosphorylation (Fig. 4 c, 
P/FC total extract
In P/FC the overall changes measured in ERKs were smaller in respect of HPC (Figs 5, 6), as observed for pCREB (see above). 2WA showed an effect of both time (F 4,109 =7.73, p<0.0001) and drug (F 1,109 =20.11, p<0.0001) on ERK1 expression and an effect of time (F 4,110 =3.56, p<0.01) and timerdrug interaction (F 4,110 =3.02, p<0.05) on ERK2. Flx did not affect ERK1/2 expression whereas Rbx up-regulated both ERK1 and ERK2 (the latter at week 1 only ; Fig. 5a, b) .
Regarding phosphorylation in total extract, 2WA showed an effect of time (F 4,97 =7.72, p<0.0001) for pERK1 and an effect of time (F 4,109 =7.19, p<0.0001), drug (F 1,109 =5.59, p<0.05) and timerdrug interaction (F 4,109 =3.84, p<0.01) for pERK2. pERK1 was up-regulated by both drugs in P/FC (starting at week 2) ; pERK2 was up-regulated by Flx starting at week 2, and by Rbx at week 1 only.
P/FC nuclear fraction
2WA highlighted a significant effect of time (F 4,109 = 6.93, p<0.0001), drug (F 1,109 =7.99, p<0.01) and timerdrug interaction (F 4,109 =4.52, p<0.01) on ERK1 expression levels ; ERK2 was also significantly modified, with an effect of time (F 4,107 =3, p<0.05), drug (F 1,107 = 52,97, p<0.0001) and timerdrug interaction (F 4,107 = 5.37, p<0.001). Whereas Flx had no significant effect on expression levels (except for ERK1 at week 1), Rbx down-regulated ERK1 and up-regulated ERK2 (Fig. 6 a, b) . Regarding phosphorylation, 2WA showed pERK2 : F 4,117 =9.68, p<0.000). Flx maximally activated both kinases in nuclear fraction after washout (week 3+1 ; Fig. 6 c, d ). Rbx up-regulated pERK2 (at weeks 1-2). Overall, in HPC (Figs 3, 4) the two drugs very early induced the activation of both ERKs at week 1 (nuclei and/or total extract), in line with early activation of CREB (see Fig. 2 ) ; for Flx, activation of ERK1 at week 1 in total extract was followed by activation at week 2 in nuclei. In P/FC (Figs. 5, 6 ) ERK activation in most cases was delayed ; activation of nuclear ERKs by Flx was postponed until after the washout week (Fig. 6 c, d ).
Early activation of nuclear CaM kinase IV by Rbx but not Flx
Several independent studies have previously shown that CaM kinase IV is one of the kinases responsible for activity-dependent phosphorylation and activation of neuronal CREB (Bito et al. 1996 ; Kasahara et al. 2001 ; Lee et al. 2005) . We have previously shown that 2-wk treatments with different antidepressants activate CaM kinase IV, while 5-wk lithium treatment down-regulates CaM kinase IV expression and its Thr 196 phosphorylation in rats (Tardito et al. 2007 ; Tiraboschi et al. 2004b) . Because CaM kinase IV has a predominant nuclear localization and directly phosphorylates CREB in the nucleus (Nakamura et al. 1995 expression and Thr 196 phosphorylation of the kinase. We found that Flx and Rbx affected nuclear CaM kinase IV levels in HPC and P/FC with different modalities. In HPC 2WA showed a significant effect of time (F 4,66 =4.32, p<0.01), drug (F 1,66 =4.25, p<0.05) and timerdrug interaction (F 4,66 =10.34, p<0.0001), whereas in P/FC only time had a significant effect (F 4,95 =20,76, p<0.0001). In detail, Flx did not change CaM kinase IV expression in HPC and up-regulated the kinase at weeks 1-3 in P/FC (Fig. 7 a, b) . Rbx induced a bimodal change in HPC, with downregulation at week 2 and up-regulation at week 3, while up-regulation in P/FC was indistinguishable from that induced by Flx.
According to 2WA the two drugs also exerted different effects on CaM kinase IV phosphorylation (Fig. 7 c, d ). In HPC, the only variable that affected the kinase phosphorylation was time (F 4,74 =7.99, p< 0.0001) whereas in P/FC we found a significant effect of time (F 4,71 =6.96, p<0.0001), drug (F 1,71 =17.45, p<0.0001) and timerdrug interaction (F 4,71 =4.75, p<0.01). Flx increased the kinase activation in HPC starting from week 2 but showed no effect in P/FC ; Rbx activated the kinase in both areas from week 1, with sustained effect at all times except for week 2 in P/FC. Overall, the profile of nuclear CaM kinase IV activation was consistent with that of early CREB phosphorylation only for Rbx in HPC. a role in the modulation of CREB transcriptional activity has been proposed, through phosphorylation of both Ser 133 and Ser 142-143 . However, its role in the regulation of CREB function is still unclear and it has been suggested that it may work, somewhat in opposition to CaM kinase IV, reducing CREB dimerization and binding to co-activator CREB-binding protein (Parker et al. 1998 ; Wu & McMurray, 2001) . We have previously shown that aCaM kinase II is differently regulated by antidepressants in distinct cellular compartments (Barbiero et al. 2007 ; Bonanno et al. 2005 ; Tiraboschi et al. 2004a, b ; see Discussion) . Here we have investigated the action of antidepressant drugs on the function of aCaM kinase II in the nucleus. We measured aCaM kinase II expression levels and Thr 286 phosphorylation (the activating residue for this kinase). In HPC, 2WA showed only an effect of time (F 4,89 =6.82, p<0.0001) on nuclear aCaM kinase II levels, with a late up-regulation for Rbx at week 3+1 ; no changes were found in P/FC (Fig. 8 a, b) .
Conversely, phosphorylation of aCaM kinase II in HPC was affected by time (F 4,56 =11.40, p<0.0001), drug (F 1,56 =15.92, p<0.001) and timerdrug interaction (F 4,56 =6.21, p<0.001). In detail, Thr 286 phosphorylation was reduced in HPC by both drugs (Fig. 8c) , at all times and more markedly by Flx, and at weeks 1 and 3+1 by Rbx.
In P/FC an effect of drug (F 1,54 =92.26, p<0.0001) and timerdrug interaction (F 4,54 =8.91, p<0.0001) was found for the kinase phosphorylation. Rbx reduced the kinase activation at all times ; Flx instead increased phosphorylation only at week. 3+1 (Fig. 8 d) . Overall, differently from the effect on CaM kinase IV, Flx in HPC and Rbx in P/FC consistently reduced the activation of nuclear aCaM kinase II at all times and after washout.
Discussion
Early activation of CREB and relevant signalling by antidepressants in HPC
In order to facilitate comparison of the temporal profiles of several variables analysed in the present work, we have graphically reported in a summary figure their time-courses for each drug treatment in the two brain areas (Fig. 9 ). For both CREB and protein kinases, for the sake of simplicity, only changes in the nuclear phospho-forms of proteins were reported in the graph. A number of results from this study were surprising. First, nuclear CREB was already maximally or submaximally phosphorylated at week 1 by both drug treatments in HPC and by Flx in P/FC (Fig. 9 a-c) . This finding was unexpected and, to our knowledge, has not been reported previously, perhaps because longer drug treatments have been carried out in most studies performed thus far. This would suggest that CREB activation is an early event during antidepressant treatment. In HPC, pCREB was induced in a bimodal way by both drugs, with two waves of activation in line with concomitant waves of activation of signalling cascades (Fig. 9 a, b) . In P/FC, pCREB did not show distinct peaks with time and the extent of induction was smaller in respect of HPC, in line with the smaller extent of activation of signalling cascades (Fig. 9 c, d) . A previous study found lesser effect of antidepressants on pCREB in prefrontal cortex in respect of HPC (Qi et al. 2008) . Considering that in most studies, including our previous works, drug treatments have usually been carried out for a single time length, future studies should consider how different lengths of treatment may affect the results, at least for measurements in the HPC. In a companion study, we investigated in the same rats treated with the two antidepressants for different time lengths the time-course of changes in the expression levels of BDNF, a gene that is under transcriptional control of CREB. We found that the level of BDNF protein in the HPC was already maximal or submaximal at week 1, showing a probable functional correlate of the early CREB activation by the antidepressants (Musazzi et al. unpublished observations) . Second, Ser 133 CREB phosphorylation in both areas returned to control values after 1-wk Rbx washout but was still maximal after 1-wk Flx washout ; again, this is in line with the temporal profile of signalling cascades, still peaking at week 3+1 with Flx but not with Rbx (compare points 3+1 in Fig. 9 a-c with those in Fig. 9 b, d ). This striking difference between the two drugs could be due to the extremely long half-life of the Flx active metabolite norfluoxetine (16¡2 d; Bolo et al. 2000) and, to our knowledge, this extended activation of CREB and signalling by Flx after washout has never been previously shown. It would be important to study a time-point at which norfluoxetine has been completely cleared from the system, to understand the reason for this sustained effect of Flx. Moreover, differences in the efficacy of the doses of respective drugs cannot be excluded.
Third, different from nuclear ERK1/2 and CaM kinase IV, the action of the two antidepressants on nuclear CaM kinase II was rather a deactivation (reduction of Thr 286 phosphorylation). This kinase is enriched in excitatory neurons and much compartmentalized (particularly at synapses) ; in previous studies we have shown that : (i) aCaM kinase II is deeply affected by antidepressants and is crucial for some functional changes induced by these drugs (e.g. inhibition of glutamate release) ; (ii) the effect of antidepressants on aCaM kinase II are quite different depending on the cellular district where the changes are measured (Barbiero et al. 2007 ; Bonanno et al. 2005 ; Tiraboschi et al. 2004a, b) . Selected splice isoforms of this kinase, such as a B CaM kinase II have a nuclear localization, and as anticipated above, the enzyme phosphorylates CREB at Ser 133 and additional residues, including Ser 142 and Ser 143 . It has been proposed that CaM kinase II may reduce the transcriptional activation of CREB ; Ser 142 phosphorylation was found to prevent recruitment of the co-transcription factor CREB-binding protein and prevent CREB dimerization, inducing its dissociation from DNA (Parker et al. 1998 ; Wu & McMurray, 2001) , although a positive role was found for Ser 142 phosphorylation in the regulation of the circadian clock (Gau et al. 2002) . Therefore, phosphorylation of CREB by nuclear aCaM kinase II might decrease its activation. In the present study we found a predominant negative regulation of nuclear aCaM kinase II activation by two antidepressants (as recently found also for a 3-wk treatment with a third antidepressant ; Molteni et al. 2008) . Contrary to CaM kinase IV, the Thr 286 phosphorylation state of aCaM kinase II was reduced by Flx in HPC and by Rbx in P/FC, concomitant with CREB activation. In P/FC, where Flx did not activate any of the other kinases, aCaM kinase II activation state also was not changed (Fig. 9c) . Taken together, these data may suggest that inactivation, rather than activation, of nuclear aCaM kinase II could facilitate CREB activation by antidepressant drugs. Additional studies are warranted to explore how the same pharmacological treatment may exert opposite effects on different CaM kinases in the nucleus.
Correlation between activation of CREB and signalling
We suggest that the possible factors for stronger activation of CREB in HPC could be linked to the different extent and timing of signalling activation (Fig. 9) . In HPC, at week 1 Flx partially activated ERK2 and maximally inactivated CaM kinase II, while ERK1 and CaM kinase IV were activated starting with week 2 (when all kinases reached submaximal activation). CREB was already activated at week 1. In the same area, Rbx induced a robust activation of ERK1, ERK2 and CaM kinase IV at week 1, with contemporary maximal activation of CREB (Fig. 9a, b) . In P/FC, Flx did not activate any of the kinases at week 1 or later times, until after washout (week 3+1) for ERK1/2 and aCaM kinase II. However, CREB was moderately activated in P/FC at all times, including week 1. Further, in P/FC Rbx induced early activation of three kinases, but with ERK1/2 somewhat less activated and less transient than in HPC, and maximal inactivation of aCaM kinase II at week 1 ; here CREB was less precociously activated (at weeks 2-3) (Fig. 9 c, d) . Overall, the present results may suggest that : (1) multiple and larger extent of signalling activation is linked to larger extent of CREB activation in the HPC (both drugs) ; (2) early activation of signalling corresponds to early CREB activation in HPC. However, in HPC CREB was maximally activated by Flx before the peak of signalling activation and in P/FC lack of activation of signalling by Flx did not block the activation of CREB. Therefore, it is possible that in some cases ERK-MAPK and CaM kinase cascades are not the main ones involved in the activation of CREB in P/FC, although previous evidence suggested a primary role for these pathways (Pittenger & Duman, 2008 ; Tardito et al. 2007 ; Tiraboschi et al. 2004b) . A further cascade involved could be that of cAMP-PKA, because PKA can also phosphorylate CREB at Ser 133 , although in previous work we have found a minor role for this kinase in antidepressant-induced phosphorylation of CREB (Tiraboschi et al. 2004 b) . Further work is warranted to clarify the possible role of other signalling cascades in these events. A limitation to this work is that we did not analyse co-localization of signalling and CREB in different subfields of HPC or layers of P/FC, which would establish a functional correlation between the two phenomena. This will be performed in a future study employing immunohistochemistry. In summary, in the present work we have analysed several intracellular mechanisms that can be employed as readout systems for the molecular/cellular action of antidepressants. Our combined results may suggest the following :
(1) Activation of nuclear CREB in HPC and P/FC seems to be an early event during antidepressant treatment, suggesting that downstream events could be mainly responsible for the delayed therapeutic effect of antidepressant drugs. (2) Early and stronger activation of signalling by Rbx in HPC corresponds to early and stronger CREB activation. (3) Early activation of CREB by Flx in P/FC occurs in the absence of contemporary activation of signalling cascades analysed here and could involve additional cascades, such as cAMP-PKA. (4) Activation of nuclear CREB by SSRIs in HPC and by NRIs in P/FC is accompanied by inactivation of nuclear aCaM kinase II, which may suggest a possible inhibitory role for this kinase on CREB.
An additional question to be addressed in future studies is how fast CREB phosphorylation can be detected during (sub)chronic treatment (e.g. <1 wk).
